drugset / Trial / NCT00570089

Microvascular Coronary Disease In Women: Impact Of Ranolazine

NCT00570089

RandomizedCrossoverDouble-blindTreatment

Summary

1. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on myocardial ischemia (Cardiac Magnetic Resonance (CMR) extent, severity. 2. To evaluate the impact of ranolazine extended-release tablets in women with subendocardial ischemia due to microvascular endothelial dysfunction on the outcomes of angina (Seattle Angina Questionnaire (SAQ), WISE angina frequency, Duke Activity Status Inventory(DASI) and SF-36).

Timeline

Start
2007-04
Primary completion
2009-12
Completion
2009-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranolazine Small molecule 500 mg Oral
Subject Ranolazine Small molecule 1000 mg Oral

Indications